PROF Stock Overview
Operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Profound Medical Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$7.96 |
| 52 Week High | CA$11.69 |
| 52 Week Low | CA$7.11 |
| Beta | 0.83 |
| 11 Month Change | -13.01% |
| 3 Month Change | -7.23% |
| 1 Year Change | -17.60% |
| 33 Year Change | -41.94% |
| 5 Year Change | 12.11% |
| Change since IPO | -21.85% |
Recent News & Updates
Shareholder Returns
| PROF | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 5.6% | -0.8% | 0.7% |
| 1Y | -17.6% | 21.2% | 32.3% |
Return vs Industry: PROF underperformed the US Medical Equipment industry which returned 21.2% over the past year.
Return vs Market: PROF underperformed the US Market which returned 32.3% over the past year.
Price Volatility
| PROF volatility | |
|---|---|
| PROF Average Weekly Movement | 6.8% |
| Medical Equipment Industry Average Movement | 8.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: PROF's share price has been volatile over the past 3 months.
Volatility Over Time: PROF's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 131 | Arun Menawat | www.profoundmedical.com |
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors.
Profound Medical Corp. Fundamentals Summary
| PROF fundamental statistics | |
|---|---|
| Market cap | US$194.25m |
| Earnings (TTM) | -US$27.59m |
| Revenue (TTM) | US$7.88m |
24.7x
P/S Ratio-7.1x
P/E RatioIs PROF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PROF income statement (TTM) | |
|---|---|
| Revenue | US$7.88m |
| Cost of Revenue | US$3.05m |
| Gross Profit | US$4.83m |
| Other Expenses | US$32.42m |
| Earnings | -US$27.59m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.13 |
| Gross Margin | 61.24% |
| Net Profit Margin | -350.14% |
| Debt/Equity Ratio | 15.2% |
How did PROF perform over the long term?
See historical performance and comparison